Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...
Cancer doctor shares which five types of the disease are most 'lethal'
A cancer expert has shared the five types of cancer which are considered the most "lethal", and claimed people diagnosed with ...
Science Daily1d
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Taiwan News1d
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has ...
Daily5d
Hepatocellular Carcinoma After Hepatitis C Cure: Study Emphasizes The Need for Long-Term Surveillance
China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...
oncnursingnews14h
Amezalpat Receives FDA Fast Track Designation for Hepatocellular Carcinoma
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
Monthly Prescribing Reference2d
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Armed robbery in Revesby3d
Target Genes Found in Canine Liver Cancer Therapy
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy ...
News Medical4d
Insilico Medicine develops highly selective FGFR2/3 dual inhibitor for cancer treatment
Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma ...